LONDON (Reuters) - AstraZeneca boosted its early-stage pipeline of experimental heart drugs on Wednesday by buying privately held U.S. biotechnology company AlphaCore Pharma, which is developing a new type of cholesterol medicine. Financial details of the acquisition by the British drugmaker's MedImmune unit were not disclosed. AstraZeneca's new CEO Pascal Soriot said last month he planned to build up the company's sparse drug pipeline by striking more deals, with cardiovascular and metabolic disease a particular priority. ...
Click here to read the rest
No comments:
Post a Comment